Patents by Inventor Gary DeCrescenzo

Gary DeCrescenzo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210393637
    Abstract: The present invention provides, inter alia, methods, kits, and pharmaceutical compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. The method comprises administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Additional methods for effecting cancer cell death are also provided.
    Type: Application
    Filed: August 30, 2021
    Publication date: December 23, 2021
    Inventors: Saurabh Saha, Dean Welsch, Gary DeCrescenzo, Jeffrey James Roix
  • Publication number: 20210338669
    Abstract: The present disclosure relates to oral compositions of Compound I or a derivative thereof. Methods of use for treating an inflammatory condition are also disclosed.
    Type: Application
    Filed: March 26, 2021
    Publication date: November 4, 2021
    Inventors: Walter SMITH, Joseph MONAHAN, Edward HELLRIEGEL, David GORDON, Heidi HOPE, John Robert SPRINGER, Gary A. DECRESCENZO
  • Patent number: 11135225
    Abstract: The present invention provides, inter alia, methods, kits, and pharmaceutical compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. The method comprises administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Additional methods for effecting cancer cell death are also provided.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: October 5, 2021
    Assignee: BIOMED VALLEY DISCOVERIES, INC.
    Inventors: Saurabh Saha, Dean Welsch, Gary DeCrescenzo, Jeffrey James Roix
  • Patent number: 11013743
    Abstract: The present invention provides, inter alia, methods, kits, and pharmaceutical compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. The method comprises administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Additional methods for effecting cancer cell death are also provided.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 25, 2021
    Assignee: BioMed Valley Discoveries, Inc.
    Inventors: Saurabh Saha, Dean Welsch, Gary DeCrescenzo, Jeffrey James Roix
  • Patent number: 11007184
    Abstract: The present invention provides, inter alia, methods, kits, and pharmaceutical compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. The method includes administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD 523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a type 2 MEK inhibitor, or other MEK inhibitors, or pharmaceutically acceptable salts thereof, to treat or ameliorate the effects of the cancer. Additional methods for effecting cancer cell death are also provided.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 18, 2021
    Assignee: BIOMED VALLEY DISCOVERIES, INC.
    Inventors: Saurabh Saha, Dean Welsch, Gary DeCrescenzo, Jeffrey James Roix
  • Patent number: 11007183
    Abstract: The present invention provides, inter alia, methods, kits, and compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. This method includes administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is an inhibitor of the PI3K/Akt pathway or a pharmaceutically acceptable salt thereof. Also provided are methods of treating or ameliorating the effects of a subject with cancer in which the subject has a somatic KRAS and a somatic PIK3CA mutation or in which the cancer is refractory to a therapy selected from RAF inhibitor therapy, MEK inhibitor therapy, and RAF and MEK inhibitor therapy.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 18, 2021
    Assignee: BIOMED VALLEY DISCOVERIES, INC.
    Inventors: Saurabh Saha, Dean Welsch, Gary DeCrescenzo, Jeffrey James Roix
  • Publication number: 20210085663
    Abstract: The present invention provides, inter alia, methods, pharmaceutical compositions, and kits for treating or ameliorating the effects of a cancer in a subject, which harbors an atypical BRAF mutation (i.e. a non-V600E/K BRAF mutation), comprising an ERK inhibitor. Also provided are methods for identifying a subject having an atypical BRAF mutant cancer who would benefit from therapy comprising an ERK inhibitor.
    Type: Application
    Filed: May 15, 2018
    Publication date: March 25, 2021
    Inventors: Gary DeCrescenzo, Dean Welsch, Saurabh Saha
  • Publication number: 20210038587
    Abstract: The present invention provides, inter alia, methods, pharmaceutical compositions, and kits for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway inhibitor therapy. Also provided are methods for identifying a subject having cancer who would benefit from therapy with an ERK inhibitor and methods for inhibiting phosphorylation of RSK in a cancer cell that is refractory or resistant to a non-ERK MAPK pathway inhibitor.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 11, 2021
    Inventors: Saurabh Saha, Dean Welsch, Gary DeCrescenzo, Jeffrey James Roix
  • Patent number: 10881646
    Abstract: The present invention provides, inter alia, methods, pharmaceutical compositions, and kits for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway inhibitor therapy. Also provided are methods for identifying a subject having cancer who would benefit from therapy with an ERK inhibitor and methods for inhibiting phosphorylation of RSK in a cancer cell that is refractory or resistant to a non-ERK MAPK pathway inhibitor.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: January 5, 2021
    Assignee: BIOMED VALLEY DISCOVERIES, INC.
    Inventors: Saurabh Saha, Dean Welsch, Gary DeCrescenzo, Jeffrey James Roix
  • Publication number: 20200339531
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Application
    Filed: July 7, 2020
    Publication date: October 29, 2020
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X.M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • Publication number: 20200297730
    Abstract: The present invention provides, inter alia, methods, kits, and pharmaceutical compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. The method comprises administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Additional methods for effecting cancer cell death are also provided.
    Type: Application
    Filed: April 23, 2020
    Publication date: September 24, 2020
    Inventors: Saurabh Saha, Dean Welsch, Gary DeCrescenzo, Jeffrey James Roix
  • Patent number: 10738027
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: August 11, 2020
    Assignees: Biomed Valley Discoveries, Inc., Vertex Pharmaceuticals Incorporated
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X. M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • Publication number: 20200199246
    Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of (a) cancer or (b) tumor vasculature in a mammal and methods of (a) treating or preventing cancer or (b) reducing tumor vasculature in a mammal are also disclosed.
    Type: Application
    Filed: March 9, 2020
    Publication date: June 25, 2020
    Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Bradley St. Croix, Steven Seaman, Saurabh Saha, Xiaoyan Michelle Zhang, Gary A. DeCrescenzo, Dean Welsch
  • Patent number: 10668055
    Abstract: The present invention provides, inter alia, methods of treating or ameliorating the effects of a cancer in a subject. The methods include administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a type 1 RAF inhibitor (such as dabrafenib) or another RAF inhibitor (such as regorafenib) or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Also provided are pharmaceutical compositions and kits for treating or ameliorating the effects of a cancer in a subject.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: June 2, 2020
    Assignee: BIOMED VALLEY DISCOVERIES, INC.
    Inventors: Saurabh Saha, Dean Welsch, Gary DeCrescenzo, Jeffrey James Roix
  • Patent number: 10604582
    Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of (a) cancer or (b) tumor vasculature in a mammal and methods of (a) treating or preventing cancer or (b) reducing tumor vasculature in a mammal are also disclosed.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: March 31, 2020
    Assignees: The United States Of America, as represented by The Secretary, Department of Health, Biomed Valley Discoveries, Inc.
    Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Bradley St. Croix, Steven Seaman, Saurabh Saha, Xiaoyan Michelle Zhang, Gary A. DeCrescenzo, Dean Welsch
  • Publication number: 20190201387
    Abstract: The present invention provides, inter alia, methods, pharmaceutical compositions, and kits for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway inhibitor therapy. Also provided are methods for identifying a subject having cancer who would benefit from therapy with an ERK inhibitor and methods for inhibiting phosphorylation of RSK in a cancer cell that is refractory or resistant to a non-ERK MAPK pathway inhibitor.
    Type: Application
    Filed: May 22, 2017
    Publication date: July 4, 2019
    Inventors: Saurabh Saha, Dean Welsch, Gary Decrescenzo, Jeffrey Roix
  • Publication number: 20190127348
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Application
    Filed: December 20, 2018
    Publication date: May 2, 2019
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X.M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • Patent number: 10196443
    Abstract: Antibodies that specifically bind TEM8 protein, conjugates thereof, and their use, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: February 5, 2019
    Assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Biomed Valley Discoveries, Inc.
    Inventors: Dimiter Dimitrov, Zhongyu Zhu, Brad St. Croix, Enrique Zudaire, Saurabh Saha, Xiaoyan Michelle Zhang, Gary Decrescenzo, Dean Welsch
  • Patent number: 10183927
    Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: January 22, 2019
    Assignees: Biomed Valley Discoveries, Inc., Vertex Pharmaceuticals Incorporated
    Inventors: Gary DeCrescenzo, Dean Welsch, Petinka I. Vlahova, Stephan X. M. Boerrigter, Alexander Aronov, Ali Keshavarz-Shokri, Alexander N. Scangas, Kathy Stavropoulos, Benjamin Littler, Irina Nikolaevna Kadiyala, Rossitza Gueorguieva Alargova
  • Publication number: 20180186890
    Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric N antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of (a) cancer or (b) tumor vasculature in a mammal and methods of (a) treating or preventing cancer or (b) reducing tumor vasculature in a mammal are also disclosed.
    Type: Application
    Filed: September 16, 2015
    Publication date: July 5, 2018
    Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Bradley St. Croix, Steven Seaman, Saurabh Saha, Xiaoyan Michelle Zhang, Gary A. DeCrescenzo, Dean Welsch